Par Pharmaceutical to Settle Off-Label Charges

By

Kristin Jones

March 5, 2013 2:26 p.m. ET

A New Jersey-based drug company, Par Pharmaceutical Co., agreed to pay $45 million to settle allegations it improperly labeled and marketed its prescription drug Megace ES to elderly patients, the U.S. Department of Justice said.

Among other things, the company was accused of criminally misbranding Megace, which was approved by the FDA to treat weight loss tied to AIDS, as a treatment for non-AIDS-related geriatric wasting.